# US 2013/0210701 A1 · Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210701 A1
- Document ID: US20130210701A1
- Status: Published application
- Kind: A1
- Application number: 13/686,725
- Filed: 2012-11-27
- Published: 2013-08-15
- Earliest claimed: 2010-04-21
- Assignees: Signature Therapeutics, Inc.
- Inventors: Thomas E. Jenkins; Craig O. Husfeld; Julie D. Seroogy; Jonathan W. Wray
- Web page: https://patentgrep.com/patent/US20130210701A1

## CPC

- A61K 47/555: {pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- C07D 489/02: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
- C07D 489/08: Oxygen atom
- C12Q 1/37: involving peptidase or proteinase
- G01N 33/5088: {of vertebrates}
- G01N 33/9486: {Analgesics, e.g. opiates, aspirine}
- G01N 2333/976: Trypsin; Chymotrypsin
- G01N 2500/00: Screening for compounds of potential therapeutic value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.

## Claims

### Claim 1

A composition comprising:
an opioid prodrug comprising an opioid covalently bound to a promoiety comprising a GI enzyme-cleavable moiety, wherein cleavage of the GI enzyme-cleavable moiety by a GI enzyme mediates release of the opioid; and
a GI enzyme inhibitor that interacts with the GI enzyme that mediates enzymatically-controlled release of the opioid from the opioid prodrug following ingestion of the composition.

### Claim 2 (depends on 1)

A dose unit comprising the composition of claim 1, wherein
the opioid prodrug and GI enzyme inhibitor are present in the dose unit in an amount effective to provide for a pre-selected pharmacokinetic (PK) profile following ingestion.

### Claim 3 (depends on 2)

The dose unit of claim 2, wherein the pre-selected PK profile comprises at least one PK parameter value that is less than the PK parameter value of opioid released following ingestion of an equivalent dosage of opioid prodrug in the absence of inhibitor.

### Claim 4 (depends on 3)

The dose unit of claim 3, wherein the PK parameter value is selected from an opioid Cmax value, an opioid exposure value, and a (1/opioid Tmax) value.

### Claim 5 (depends on 2)

The dose unit of claim 2, wherein the dose unit provides for a pre-selected PK profile following ingestion of at least two dose units.

### Claim 6 (depends on 5)

The dose unit of claim 5, wherein the pre-selected PK profile is modified relative to the PK profile following ingestion of an equivalent dosage of opioid prodrug in the absence of inhibitor.

### Claim 7 (depends on 5)

The dose unit of claim 5, wherein the dose unit provides that ingestion of an increasing number of the dose units provides for a linear PK profile.

### Claim 8 (depends on 5)

The dose unit of claim 5, wherein the dose unit provides that ingestion of an increasing number of the dose units provides for a nonlinear PK profile.

### Claim 9 (depends on 5)

The dose unit of claim 5, wherein the PK parameter value is selected from an opioid Cmax value, a (1/opioid Tmax) value, and an opioid exposure value.

### Claim 10 (depends on 1)

A composition comprising:
a container suitable for containing a composition for administration to a patient; and
a dose unit comprising the composition of claim 1 disposed within the container.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the composition is a dose unit having a total weight of from 1 microgram to 2 grams.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the composition has a combined weight of opioid prodrug and GI enzyme inhibitor of from 0.1% to 99% per gram of the composition.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(I)
X—C(O)—NR1—(C(R2)(R3))n—NH—C(O)—CH(R4)—NH(R5) (PC-(I))
or a pharmaceutically acceptable salt thereof, wherein:
X represents a residue of a phenolic opioid, wherein the hydrogen atom of the phenolic hydroxyl group is replaced by a covalent bond to —C(O)—NR1—(C(R2)(R3))n—NH—C(O)—CH(R4)—NH(R5);
R1 represents a (1-4C)alkyl group;
R2 and R3 each independently represents a hydrogen atom or a (1-4C)alkyl group;
n represents 2 or 3;
R4 represents —CH2CH2CH2NH(C═NH)NH2 or —CH2CH2CH2CH2NH2, the configuration of the carbon atom to which R4 is attached corresponding with that in an L-amino acid; and
R5 represents a hydrogen atom, an N-acyl group, or a residue of an amino acid, a dipeptide, or an N-acyl derivative of an amino acid or dipeptide.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(IIa):
X—C(O)—NR1—(C(R2)(R3))n—NH—C(O)—CH(R4)—NH(R5) (PC-(IIa))
or a pharmaceutically acceptable salt thereof, wherein:
X represents a residue of a phenolic opioid, wherein the hydrogen atom of the phenolic hydroxyl group is replaced by a covalent bond to —C(O)—NR1—(C(R2)(R3))n—NH—C(O)—CH(R4)—NH(R5);
R1 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R3 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R2 and R3 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R2 or R3 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n represents an integer from 2 to 4;
R4 represents —CH2CH2CH2NH(C═NH)NH2 or —CH2CH2CH2CH2NH2, the configuration of the carbon atom to which R4 is attached corresponding with that in an L-amino acid; and
R5 represents a hydrogen atom, an N-acyl group (including N-substituted acyl), a residue of an amino acid, a dipeptide, or an N-acyl derivative (including N-substituted acyl derivative) of an amino acid or dipeptide.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(IIb):
X—C(O)—NR1—(C(R2)(R3))n—NH—C(O)—CH(R4)—NH(R5) (PC-(IIb))
or a pharmaceutically acceptable salt thereof, wherein:
X represents a residue of a phenolic opioid, wherein the hydrogen atom of the phenolic hydroxyl group is replaced by a covalent bond to —C(O)—NR1—(C(R2)(R3))n—NH—C(O)—CH(R4)—NH(R5);
R1 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R3 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R2 and R3 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group, or two R2 or R3 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl or substituted cycloalkyl group;
n represents an integer from 2 to 4;
R4 represents —CH2CH2CH2NH(C═NH)NH2 or —CH2CH2CH2CH2NH2, the configuration of the carbon atom to which R4 is attached corresponding with that in an L-amino acid; and
R5 represents a hydrogen atom, an N-acyl group (including N-substituted acyl), a residue of an amino acid, a dipeptide, or an N-acyl derivative (including N-substituted acyl derivative) of an amino acid or dipeptide.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(III):
X—C(O)—NR1—(C(R2)(R3))n—NH—C(O)—CH(R4)—NH(R5) (PC-(III))
or pharmaceutically acceptable salt thereof, wherein:
X represents a residue of a phenolic opioid, wherein the hydrogen atom of the phenolic hydroxyl group is replaced by a covalent bond to —C(O)—NR1—(C(R2)(R3))n—NH—C(O)—CH(R4)—NH(R5);
R1 represents a (1-4C)alkyl group;
R2 and R3 each independently represents a hydrogen atom or a (1-4C)alkyl group;
n represents 2 or 3;
R4 represents —CH2CH2CH2NH(C═NH)NH2 or —CH2CH2CH2CH2NH2, the configuration of the carbon atom to which R4 is attached corresponding with that in an L-amino acid; and
R5 represents a hydrogen atom, an N-acyl group (including N-substituted acyl), a residue of an amino acid, a dipeptide, or an N-acyl derivative (including N-substituted acyl derivative) of an amino acid or dipeptide.

### Claim 17 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(IV):
or pharmaceutically acceptable salt thereof, wherein:
Ra is hydrogen or hydroxyl;
Rb is oxo (═O) or hydroxyl;
the dashed line is a double bond or single bond;
R1 represents a (1-4C)alkyl group;
R2 and R3 each independently represents a hydrogen atom or a (1-4C)alkyl group;
n represents 2 or 3;
R4 represents —CH2CH2CH2NH(C═NH)NH2 or —CH2CH2CH2CH2NH2, the configuration of the carbon atom to which R4 is attached corresponding with that in an L-amino acid; and
R5 represents a hydrogen atom, an N-acyl group, or a residue of an amino acid, a dipeptide, or an N-acyl derivative of an amino acid or dipeptide.

### Claim 18 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(Va):
or pharmaceutically acceptable salt thereof, wherein:
Ra is hydrogen or hydroxyl;
Rb is oxo (═O) or hydroxyl;
the dashed line is a double bond or single bond;
R1 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R3 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R2 and R3 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R2 or R3 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n represents an integer from 2 to 4;
R4 represents —CH2CH2CH2NH(C═NH)NH2 or —CH2CH2CH2CH2NH2, the configuration of the carbon atom to which R4 is attached corresponding with that in an L-amino acid; and
R5 represents a hydrogen atom, an N-acyl group (including N-substituted acyl), a residue of an amino acid, a dipeptide, or an N-acyl derivative (including N-substituted acyl derivative) of an amino acid or dipeptide.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(Vb):
or pharmaceutically acceptable salt thereof, wherein:
Ra is hydrogen or hydroxyl;
Rb is oxo (═O) or hydroxyl;
the dashed line is a double bond or single bond;
R1 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R3 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R2 and R3 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group, or two R2 or R3 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl or substituted cycloalkyl group;
n represents an integer from 2 to 4;
R4 represents —CH2CH2CH2NH(C═NH)NH2 or —CH2CH2CH2CH2NH2, the configuration of the carbon atom to which R4 is attached corresponding with that in an L-amino acid; and
R5 represents a hydrogen atom, an N-acyl group (including N-substituted acyl), a residue of an amino acid, a dipeptide, or an N-acyl derivative (including N-substituted acyl derivative) of an amino acid or dipeptide.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(VI):
or pharmaceutically acceptable salt thereof, wherein:
Ra is hydrogen or hydroxyl;
Rb is oxo (═O) or hydroxyl;
the dashed line is a double bond or single bond;
R1 represents a (1-4C)alkyl group;
R2 and R3 each independently represents a hydrogen atom or a (1-4C)alkyl group;
n represents 2 or 3;
R4 represents —CH2CH2CH2NH(C═NH)NH2 or —CH2CH2CH2CH2NH2, the configuration of the carbon atom to which R4 is attached corresponding with that in an L-amino acid; and
R5 represents a hydrogen atom, an N-acyl group (including N-substituted acyl), a residue of an amino acid, a dipeptide, or an N-acyl derivative (including N-substituted acyl derivative) of an amino acid or dipeptide.

### Claim 21 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(VII):
X—C(O)—NR1—(C(R2)(R3))n—NH—R6 (PC-(VII))
or a pharmaceutically acceptable salt thereof, wherein:
X represents a residue of a phenolic opioid, wherein the hydrogen atom of the phenolic hydroxyl group is replaced by a covalent bond to —C(O)—NR1—(C(R2)(R3))n—NH—R6;
R1 represents a (1-4C)alkyl group;
R2 and R3 each independently represents a hydrogen atom or a (1-4C)alkyl group;
n represents 2 or 3; and
R6 is a trypsin-cleavable moiety.

### Claim 22 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(VIII):
X—C(O)—NR1—(C(R2)(R3))n—NH—R6 (PC-(VIII))
or a pharmaceutically acceptable salt thereof, wherein:
X represents a residue of a phenolic opioid, wherein the hydrogen atom of the phenolic hydroxyl group is replaced by a covalent bond to —C(O)—NR1—(C(R2)(R3))n—NH—R6;
R1 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R3 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R2 and R3 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R2 or R3 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n represents an integer from 2 to 4; and
R6 is a trypsin-cleavable moiety.

### Claim 23 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(IX):
or pharmaceutically acceptable salt thereof, wherein:
Ra is hydrogen or hydroxyl;
Rb is oxo (═O) or hydroxyl;
the dashed line is a double bond or single bond;
R1 represents a (1-4C)alkyl group;
R2 and R3 each independently represents a hydrogen atom or a (1-4C)alkyl group;
n represents 2 or 3; and
R6 is a trypsin-cleavable moiety.

### Claim 24 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(X):
or pharmaceutically acceptable salt thereof, wherein:
Ra is hydrogen or hydroxyl;
Rb is oxo (═O) or hydroxyl;
the dashed line is a double bond or single bond;
R1 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R3 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R2 and R3 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R2 or R3 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n represents an integer from 2 to 4; and
R6 is a trypsin-cleavable moiety.

### Claim 25 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(XI):
X—C(O)—NR1—(C(R2)(R3))n—NH—R6 (PC-(XI))
or a pharmaceutically acceptable salt thereof, in which:
X represents a residue of a phenolic opioid, wherein the hydrogen atom of the phenolic hydroxyl group is replaced by a covalent bond to —C(O)—NR1—C(R2)(R3))n—NH—R6;
R1 represents a (1-4C)alkyl group;
R2 and R3 each independently represents a hydrogen atom or a (1-4C)alkyl group;
n represents 2 or 3; and
R6 is a GI enzyme-cleavable moiety.

### Claim 26 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(XII):
X—C(O)—NR1—(C(R2)(R3))n—NH—R6 (PC-(XII))
or a pharmaceutically acceptable salt thereof, in which:
X represents a residue of a phenolic opioid, wherein the hydrogen atom of the phenolic hydroxyl group is replaced by a covalent bond to —C(O)—NR1—(C(R2)(R3))n—NH—R6;
R1 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R3 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R2 and R3 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R2 or R3 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n represents an integer from 2 to 4; and
R6 is a GI enzyme-cleavable moiety.

### Claim 27 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(XIII):
or pharmaceutically acceptable salt thereof, in which:
Ra is hydrogen or hydroxyl;
Rb is oxo (═O) or hydroxyl;
the dashed line is a double bond or single bond;
R1 represents a (1-4C)alkyl group;
R2 and R3 each independently represents a hydrogen atom or a (1-4C)alkyl group;
n represents 2 or 3; and
R6 is a GI enzyme-cleavable moiety.

### Claim 28 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(XIV):
or pharmaceutically acceptable salt thereof, in which:
Ra is hydrogen or hydroxyl;
Rb is oxo (═O) or hydroxyl;
the dashed line is a double bond or single bond;
R1 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R3 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R2 and R3 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R2 or R3 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n represents an integer from 2 to 4; and
R6 is a GI enzyme-cleavable moiety.

### Claim 29 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(XV):
wherein:
X is a phenolic opioid, wherein the hydrogen atom of the hydroxyl group is replaced by a covalent bond to —C(O)—Y—(C(R1)(R2))n—N—(R3)(R6);
Y is —NR5—, —O— or —S—;
n is an integer from 1 to 4;
each R1, R2, R3 and R5 is independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, or R1 and R2 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group;
R6 is
each R4 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R4 and R7 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R7 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl;
p is an integer from 1 to 10;
each W is independently —NR8—, —O— or —S—; and
each R8 is independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, or optionally,
each R4 and R8 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring.

### Claim 30 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(XVI):
or salts, solvates or hydrates thereof wherein:
X is an opioid comprising a phenol wherein a hydrogen atom of the phenol is replaced by a covalent bond to —(CR12R13)—Y—Z—R11;
R12 and R13 are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
Y is aryl, heteroaryl or arylaryl optionally substituted with one or more —F, —Cl, —Br, —I, —R14, —O−, —OR14, —SR14, —S−, —NR14R15, —CF3, —CN, —OCN, —SCN, —NO, —NO2, —N3, —S(O)2O−, —S(O)2OH, —S(O)2R14, —OS(O2)O−, —OS(O)2R14, —P(O)(O−)2, —P(O)(OR14)(O−), —OP(O)(OR14)(OR15), —C(O)R14, —C(S)R14, —C(O)OR14, —C(O)NR14R15, —C(O)O−, —C(S)OR14, —NR16C(O)NR14R15, —NR16C(S)NR14R15, —NR17C(NR16)NR15R14 or —C(NR16)NR15R14;
R14, R15, R16 and R17 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R14 and R15 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
Z is N(R18)—, —O— or —S—;
R18 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or
each W is independently —NR20—, —O— or —S—;
each R19 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R19 and R20 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each R20 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R20 and R21 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R21 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl;
n is an integer from 0 to 5;
R11 is
each U is independently —NR23—, —O— or —S—;
each R22 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R22 and R23 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each R23 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R23 and R24 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R24 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and
o is an integer from 1 to 100;
provided that Z is oriented para or ortho to X—(CR12R13)— and that both R18 and R11 are not hydrogen.

### Claim 31 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(XVII):
or salts, solvates or hydrates thereof wherein:
X is an opioid comprising a phenol, wherein X is connected by the phenol;
R12 and R13 are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
Rk26 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R14, —O−, —OR14, —SR14, —S−, —NR14R15, —CF3, —CN, —OCN, —SCN, —NO, —NO2, —N3, —S(O)2O, —S(O)2OH, —S(O)2R14, —OS(O2)O−, —OS(O)2R14, —P(O)(O−)2, —P(O)(OR14)(O−), —OP(O)(OR14)(OR15), —C(O)R14, —C(S)R14, —C(O)OR14, —C(O)NR14R15, —C(O)O−, —C(S)OR14, —NR16C(O)NR14R15, —NR16C(S)NR14R15, —NR17C(NR16)NR15R14 and —C(NR16)NR15R14, and k is 0, 1, 2, 3, or 4;
R14, R15, R16 and R17 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R4 and R5 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R18 is hydrogen or methyl;
R22 is a side chain of an amino acid or a derivative of a side chain of an amino acid;
each U is independently —NR23—, —O— or —S—;
each R23 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R23 and R24 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and
R24 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and
o is an integer from 1 to 100.

### Claim 32 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula PC-(XVIII):
X—C(R31a)(R32a))—Ar—Z—C(O)—Y—(C(R31)(R32))n—N—(R33)(R34)A- (PC-(XVIII)
or a salt, hydrate or solvate thereof wherein:
X is an opioid comprising a phenol wherein a hydrogen atom of the phenol is replaced by a covalent bond to —(C(R31a)(R32a)—Ar—Z—C(O)—Y—(C(R31)(R32))n—N—(R33)(R34);
R31a and R32a are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
Ar is aryl, heteroaryl or arylaryl optionally substituted with one or more —F, —Cl, —Br, —I, —R34a, —O−, —OR34a, —SR34a, —S—, —NR34aR35a, —CF3, —CN, —OCN, —SCN, —NO, —NO2, —N3, —S(O)2O′, —S(O)2OH, —S(O)2R34a, —OS(O2)O″, —OS(O)2R34a, —P(0)(0″)2, —P(O)(OR34a)(O″), —OP(O)(OR34a)(OR35a), —C(0)R34a, —C(S)R34a, —C(O)OR34a, —C(O)NR34aR35a, —C(O)O; —C(S)OR34a, —NR36aC(O)NR34aR35a, —NR36aC(S)NR34aR35a, —NR37aC(NR36a)NR35aR34a or —C(NR36a)NR35aR34a, or tethered to a polymer;
R34a, R35a, R36a and R37a are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R34 and R35 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
Z is O, S or NH;
Y is —NR35—, —O— or —S—;
n is an integer from 1 to 10;
each R31, R32, R33 and R35 is independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, or R31 and R32 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group, or two R31 or R32 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl or substituted cycloalkyl group;
R34 is
each R36 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R36 and R37 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R37 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl;
p is an integer from 1 to 5;
each W is independently —NR38—, —O— or —S—;
each R38 is independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, or optionally, each R36 and R38 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and
A′ represents an anion.

### Claim 33 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(Ia):
wherein:
Ra is hydrogen or hydroxyl;
R5 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R1 and R2 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R1 or R2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n is an integer from 2 to 4;
R3 is hydrogen or (1-4C)alkyl;
R4 is
each R6 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl, or optionally, R6 and R7 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each W is independently —NR8—, —O— or —S—;
each R8 is independently selected from hydrogen, alkyl, substituted alkyl, aryl and substituted aryl, or optionally, each R6 and R8 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
p is an integer from one to 100; and
R7 is selected from hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, and substituted arylalkyl;
or a salt, hydrate or solvate thereof.

### Claim 34 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(Ib):
wherein:
Ra is hydrogen or hydroxyl;
R5 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R1 and R2 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group, or two R1 or R2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl or substituted cycloalkyl group;
n is an integer from 2 to 4;
R3 is hydrogen or (1-4C)alkyl;
R4 is
each R6 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl, or optionally, R6 and R7 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each W is independently —NR8—, —O— or —S—;
each R8 is independently selected from hydrogen, alkyl, substituted alkyl, aryl and substituted aryl, or optionally, each R6 and R8 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
p is an integer from one to 100; and
R7 is selected from hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, and substituted arylalkyl;
or a salt, hydrate or solvate thereof.

### Claim 35 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(II):
wherein:
Ra is hydrogen or hydroxyl;
R5 is selected from (1-6C)alkyl, (1-6C) substituted alkyl, —(CH2)q(C6H4)—COOH, —(CH2)q(C6H4)—COOCH3, and —(CH2)q(C6H4)—COOCH2CH3, where q is an integer from one to 10;
each R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R1 and R2 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group, or two R1 or R2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl or substituted cycloalkyl group;
n is 2 or 3;
R3 is hydrogen;
R4 is a residue of an L-amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine, or a residue of an N-acyl derivative of any of said amino acids; or a residue of a peptide composed of at least two L-amino acid residues selected independently from alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine or a residue of an N-acyl derivative thereof.

### Claim 36 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(IIIa):
wherein:
X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond to —C(O)—NR5—(C(R1)(R2))n—NR3R4;
R5 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R1 and R2 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R2 or R3 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n is an integer from 2 to 4;
R3 is hydrogen or (1-4C) alkyl;
R4 is
each R6 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl, or optionally, R6 and R7 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each W is independently —NR8—, —O— or —S—;
each R8 is independently selected from hydrogen, alkyl, substituted alkyl, aryl and substituted aryl, or optionally, each R6 and R8 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
p is an integer from one to 100; and
R7 is selected from hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, and substituted arylalkyl;
or a salt, hydrate or solvate thereof.

### Claim 37 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(IIIb):
wherein:
X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond to —C(O)—NR5—(C(R1)(R2))n—NR3R4;
R5 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R1 and R2 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group, or two R1 or R2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl or substituted cycloalkyl group;
n is an integer from 2 to 4;
R3 is hydrogen or (1-4C) alkyl;
R4 is
each R6 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl, or optionally, R6 and R7 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each W is independently —NR8—, —O— or —S—;
each R8 is independently selected from hydrogen, alkyl, substituted alkyl, aryl and substituted aryl, or optionally, each R6 and R8 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
p is an integer from one to 100; and
R7 is selected from hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, and substituted arylalkyl;
or a salt, hydrate or solvate thereof.

### Claim 38 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(IV):
wherein:
X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond to —C(O)—NR5—(C(R1)(R2))n—NR3R4;
R5 is selected from (1-6C)alkyl, (1-6C) substituted alkyl, —(CH2)q(C6H4)—COOH, —(CH2)q(C6H4)—COOCH3, and —(CH2)q(C6H4)—COOCH2CH3, where q is an integer from one to 10;
each R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R1 and R2 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group, or two R1 or R2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl or substituted cycloalkyl group;
n is 2 or 3;
R3 is hydrogen;
R4 is a residue of an L-amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine, or a residue of an N-acyl derivative of any of said amino acids; or a residue of a peptide composed of at least two L-amino acid residues selected independently from alanine, arginine, asparagine, aspartic acid, cysteine, glycine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine or a residue of an N-acyl derivative thereof;
or a salt, hydrate or solvate thereof.

### Claim 39 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(Va):
wherein:
X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond to —C(O)—NR5—(C(R1)(R2))n—NR3R4;
R5 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R1 and R2 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R1 or R2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n is an integer from 2 to 4;
R3 is hydrogen;
R4 is a trypsin-cleavable moiety;
or a salt, hydrate or solvate thereof.

### Claim 40 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(Vb):
wherein:
X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond to —C(O)—NR5—(C(R1)(R2))n—NR3R4;
R5 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R1 and R2 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R1 or R2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n is an integer from 2 to 4;
R3 is hydrogen;
R4 is a GI enzyme-cleavable moiety;
or a salt, hydrate or solvate thereof.

### Claim 41 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(VI):
wherein:
X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond to —C(O)—Y—(C(R1)(R2))n—NR3R4;
Y is —NR5—, —O— or —S—;
n is an integer from 1 to 4;
each R1, R2, R3 and R5 is independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, or R1 and R2 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group;
R4 is
each R6 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R6 and R7 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R7 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl;
p is an integer from 1 to 10;
each W is independently —NR8—, —O— or —S—; and
each R8 is independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, or optionally, each R6 and R8 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring.

### Claim 42 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(VII):
or salts, solvates or hydrates thereof wherein:
X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond —(CR12R13)—Y—Z—R11;
R12 and R13 are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
Y is aryl, heteroaryl or arylaryl optionally substituted with one or more —F, —Cl, —Br, —I, —R14, —O−, —OR14, —SR14, —S−, —NR14R15, —CF3, —CN, —OCN, —SCN, —NO, —NO2, —N3, —S(O)2O−, —S(O)2OH, —S(O)2R14, —OS(O2)O−, —OS(O)2R14, —P(O)(O−)2, —P(O)(OR14)(O−), —OP(O)(OR14)(OR15), —C(O)R14, —C(S)R14, —C(O)OR14, —C(O)NR14R15, —C(O)O−, —C(S)OR14, —NR16C(O)NR14R15, —NR16C(S)NR14R15, —NR17C(NR16)NR15R14 or —C(NR16)NR15R14;
R14, R15, R16 and R17 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R14 and R15 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
Z is N(R18)—, —O— or —S—;
R18 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or
each W is independently —NR20—, —O— or —S—;
each R19 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R19 and R20 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each R20 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R20 and R21 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R21 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl;
n is an integer from 0 to 5;
R11 is
each U is independently —NR23—, —O— or —S—;
each R22 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R22 and R23 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each R23 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, or optionally, R23 and R24 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R24 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and
o is an integer from 1 to 100;
provided that Z is oriented para or ortho to X—(CR12R13)— and that both R18 and R11 are not hydrogen.

### Claim 43 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(VIII):
or salts, solvates or hydrates thereof wherein:
X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond to —(CR12R13)—Y—Z—R11;
R12 and R13 are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
Rk26 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R14, —O−, —OR14, —SR14, —S−, —NR14R15, —CF3, —CN, —OCN, —SCN, —NO, —NO2, —N3, —S(O)2O−, —S(O)2OH, —S(O)2R14, —OS(O2)O−, —OS(O)2R14, —P(O)(O−)2, —P(O)(OR14)(O−), —OP(O)(OR14)(OR15), —C(O)R14, —C(S)R14, —C(O)OR14, —C(O)NR14R15, —C(O)O−, —C(S)OR14, —NR16C(O)NR14R15, —NR16C(S)NR14R15, —NR17C(NR16)NR15R14 and —C(NR16)NR15R14, and k is 0, 1, 2, 3, or 4;
R14, R15, R16 and R17 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R4 and R5 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R18 is hydrogen or methyl;
R22 is a side chain of an amino acid or a derivative of a side chain of an amino acid;
each U is independently —NR23—, —O— or —S—;
each R23 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R23 and R24 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and
R24 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and
o is an integer from 1 to 100.

### Claim 44 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula KC-(IX):
X—C(R31a)(R32a))—Ar—Z—C(O)—Y—(C(R31)(R32))n—N—(R33)(R34)A- (KC-(IX))
or a salt, hydrate or solvate thereof wherein:
X represents a residue of a ketone-containing opioid, wherein the hydrogen atom of the corresponding enolic group of the ketone is replaced by a covalent bond to —(C(R31a)(R32a)—Ar—Z—C(O)—Y—(C(R31)(R32))n—N—(R33)(R34);
R31a and R32a are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
Ar is aryl, heteroaryl or arylaryl optionally substituted with one or more —F, —Cl, —Br, —I, —R34a, —O−, —OR34a, —SR34a, —S—, —NR34aR35a, —CF3, —CN, —OCN, —SCN, —NO, —NO2, —N3, —S(O)2O′, —S(O)2OH, —s(O)2R34a, —OS(O2)O″, —OS(O)2R34a, —P(0)(0″)2, —P(O)(OR34a)(O″), —OP(O)(OR34a)(OR35a), —C(0)R34a, —C(S)R34a, —C(O)OR34a, —C(O)NR34aR35a, —C(O)O; —C(S)OR34a, —NR36aC(O)NR34aR35a, —NR36aC(S)NR34aR35a, —NR37aC(NR36a)NR35aR34a or —C(NR36a)NR35aR34a, or tethered to a polymer;
R34a, R35a, R36a and R37a are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R34 and R35 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
Z is O, S or NH;
Y is —NR35—, —O— or —S—;
n is an integer from 1 to 10;
each R31, R32, R33 and R35 is independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, or R31 and R32 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group, or two R31 or R32 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl or substituted cycloalkyl group;
R34 is
each R36 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R36 and R37 together with
the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R37 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl;
p is an integer from 1 to 5;
each W is independently —NR38—, —O— or —S—;
each R38 is independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, or optionally, each R36 and R38 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and
A′ represents an anion.

### Claim 45 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula QS-(I):
or salts, solvates or hydrates thereof wherein:
X is an opioid comprising an amine, wherein a hydrogen atom of the primary or secondary amine is replaced by a covalent bond to —(CR12R13)—Y—Z—R11 or a lone pair of electrons of a tertiary amine is replaced by a covalent bond to —(CR12R13)—Y—Z—R11;
R12 and R13 are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
Y is aryl, heteroaryl or arylaryl optionally substituted with one or more —F, —Cl, —Br, —I, —R14, —O−, —OR14, —SR14, —S−, —NR14R15, —CF3, —CN, —OCN, —SCN, —NO, —NO2, —N3, —S(O)2O−, —S(O)2OH, —S(O)2R14, —OS(O2)O−, —OS(O)2R14, —P(O)(O−)2, —P(O)(OR14)(O−), —OP(O)(OR14)(OR15), —C(O)R14, —C(S)R14, —C(O)OR14, —C(O)NR14R15, —C(O)O−, —C(S)OR14, —NR16C(O)NR14R15, —NR16C(S)NR14R15, —NR17C(NR16)NR15R14 or —C(NR16)NR15R14;
R14, R15, R16 and R17 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R14 and R15 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
Z is N(R18)—, —O— or —S—;
R18 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or
each W is independently —NR20—, —O— or —S—;
each R19 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R19 and R20 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each R20 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R20 and R21 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R21 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl;
n is an integer from 0 to 5;
R11 is
each U is independently —NR23—, —O— or —S—;
each R22 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R22 and R23 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each R23 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R23 and R24 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R24 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and
o is an integer from 1 to 100;
provided that Z is oriented para or ortho to X—(CR12R13)— and that both R18 and R11 are not hydrogen.

### Claim 46 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula QS-(II):
or salts, solvates or hydrates thereof wherein:
X is an opioid comprising an amine, wherein a hydrogen atom of the primary or secondary amine is replaced by a covalent bond to —(CR12R13)—Y—Z—R11 or a lone pair of electrons of a tertiary amine is replaced by a covalent bond to —(CR12R13)—Y—Z—R11;
R12 and R13 are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
Rk26 are each independently selected from the group consisting of one or more of —F, —Cl, —Br, —I, —R14, —O−, —OR14, —SR14, —S−, —NR14R15, —CF3, —CN, —OCN, —SCN, —NO, —NO2, —N3, —S(O)2O−, —S(O)2OH, —S(O)2R14, —OS(O2)O−, —OS(O)2R14, —P(O)(O−)2, —P(O)(OR14)(O−), —OP(O)(OR14)(OR15), —C(O)R14, —C(S)R14, —C(O)OR14, —C(O)NR14R15, —C(O)O−, —C(S)OR14, —NR16C(O)NR14R15, —NR16C(S)NR14R15, —NR17C(NR16)NR15R14 and —C(NR16)NR15R14, and k is 0, 1, 2, 3, or 4;
R14, R15, R16 and R17 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R4 and R5 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R18 is hydrogen or methyl;
R22 is a side chain of an amino acid or a derivative of a side chain of an amino acid;
each U is independently —NR23—, —O— or —S—;
each R23 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or optionally, R23 and R24 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and
R24 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl; and
o is an integer from 1 to 100.

### Claim 47 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula QS-(III):
X—C(R31a)(R32a))—Ar—Z—C(O)—Y—(C(R31)(R32))n—N—(R33)(R34)A- (QS-(III))
or a salt, hydrate or solvate thereof wherein:
X is a residue of an opioid wherein the lone pair of electrons of the amino nitrogen is replaced with a bond to —(C(R31a)(R32a)—Ar—Z—C(O)—Y—(C(R31)(R32))n—N—(R33)(R34);
R31a and R32a are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
Ar is aryl, heteroaryl or arylaryl optionally substituted with one or more —F, —Cl, —Br, —I, —R34a, —O−, —OR34a, —SR34a, —S—, —NR34aR35a, —CF3, —CN, —OCN, —SCN, —NO, —NO2, —N3, —S(O)2O′, —S(O)2OH, —S(O)2R34a, —OS(O2)O″, —OS(O)2R34a, —P(0)(0″)2, —P(O)(OR34a)(O″), —OP(O)(OR34a)(OR35a), —C(0)R34a, —C(S)R34a, —C(O)OR34a, —C(O)NR34aR35a, —C(O)O; —C(S)OR34a, —NR36aC(O)NR34aR35a, —NR36aC(S)NR34aR35a, —NR37aC(NR36a)NR35aR34a or —C(NR36a)NR35aR34a, or tethered to a polymer;
R34a, R35a, R36a and R37a are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R34 and R35 together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
Z is O, S or NH;
Y is —NR35—, —O— or —S—;
n is an integer from 1 to 10;
each R31, R32, R33 and R35 is independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, or R31 and R32 together with the carbon to which they are attached form a cycloalkyl or substituted cycloalkyl group, or two R31 or R32 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl or substituted cycloalkyl group;
R34 is
each R36 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, or optionally, R36 and R37 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R37 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl;
p is an integer from 1 to 5;
each W is independently —NR38—, —O— or —S—;
each R38 is independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, or optionally, each R36 and R38 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and
A′ represents an anion.

### Claim 48 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula AE-(I):
wherein:
X represents a residue of an amide-containing opioid, wherein —C(O)—NR5—(C(R1)(R2))n—NR3R4 is connected to the amide-containing opioid through the oxygen of the amide group, wherein the amide group is converted to an amide enol or an imine tautomer;
R5 is selected from alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, aryl and substituted aryl;
each R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R1 and R2 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R1 or R2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n is an integer from 2 to 4;
R3 is hydrogen or (1-4C)alkyl;
R4 is
each R6 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl, or optionally, R6 and R7 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each W is independently —NR8—, —O— or —S—;
each R8 is independently selected from hydrogen, alkyl, substituted alkyl, aryl and substituted aryl, or optionally, each R6 and R8 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
p is an integer from one to 100; and
R7 is selected from hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, and substituted arylalkyl;
or a salt, hydrate or solvate thereof.

### Claim 49 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula AE-(II):
wherein:
X represents a residue of an amide-containing opioid, wherein —C(O)—NRS—(C(R1)(R2))n—NR3R4 is connected to the amide-containing opioid through the oxygen of the amide group, wherein the amide group is converted to an amide enol or an imine tautomer;
R5 is selected from (1-6C)alkyl, (1-6C) substituted alkyl, —(CH2)q(C6H4)—COOH, —(CH2)q(C6H4)—COOCH3, and —(CH2)q(C6H4)—COOCH2CH3, where q is an integer from one to 10;
each R1 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
each R2 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, acyl, and aminoacyl;
or R1 and R2 together with the carbon to which they are attached form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group, or two R1 or R2 groups on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a cycloalkyl, substituted cycloalkyl, aryl, or substituted aryl group;
n is 2 or 3;
R3 is hydrogen;
R4 is a GI enzyme-cleavable moiety;
or a salt, hydrate or solvate thereof.

### Claim 50 (depends on 1)

The composition of claim 1, wherein the opioid prodrug is a compound of formula AE-(III):
wherein:
X represents a residue of an amide-containing opioid, wherein —CO—C(R6)—NR8R7 is connected to the amide-containing opioid through the oxygen of the amide group, wherein the amide group is converted to an amide enol or an imine tautomer;
each R6 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl, or optionally, R6 and R7 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
each R8 is independently selected from hydrogen, alkyl, substituted alkyl, aryl and substituted aryl, or optionally, each R6 and R8 independently together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
R7 is selected from hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, and substituted arylalkyl;
or a salt, hydrate or solvate thereof.

### Claim 51 (depends on 1)

A method to treat a patient comprising administering a pharmaceutical composition or dose unit comprising the composition of claim 1 to a patient in need thereof.

### Claim 52

A method of making a dose unit, the method comprising:
combining in a dose unit:
an opioid prodrug comprising an opioid covalently bound to a promoiety cleavable by a GI enzyme, wherein cleavage of the promoiety by the GI enzyme mediates release of the opioid from the opioid prodrug; and
a GI enzyme inhibitor that interacts with the enzyme that mediates enzymatically-controlled release of the opioid from the opioid prodrug;
wherein the opioid prodrug and GI enzyme inhibitor are present in the dose unit in an amount effective to attenuate release of the opioid from the opioid prodrug such that ingestion of multiples of dose units by a patient does not provide a proportional release of opioid.

### Claim 53 (depends on 52)

A method of claim 52, wherein said release of opioid is decreased compared to release of opioid by an equivalent dosage of opioid prodrug in the absence of inhibitor.

### Claim 54

A method for identifying an opioid prodrug and a GI enzyme inhibitor suitable for formulation in a dose unit, the method comprising:
combining an opioid prodrug, a GI enzyme inhibitor, and GI enzyme in a reaction mixture, wherein the opioid prodrug comprises an opioid covalently bound to a promoiety comprising a GI enzyme-cleavable moiety, wherein cleavage of the GI enzyme-cleavable moiety by the enzyme mediates release of the opioid; and
detecting opioid prodrug conversion,
wherein a decrease in opioid prodrug conversion in the presence of the GI enzyme inhibitor as compared to opioid prodrug conversion in the absence of the GI enzyme inhibitor indicates the opioid prodrug and GI enzyme inhibitor are suitable for formulation in a dose unit.

### Claim 55

A method for identifying an opioid prodrug and a GI enzyme inhibitor suitable for formulation in a dose unit, the method comprising:
administering to an animal an opioid prodrug and a GI enzyme inhibitor, wherein the opioid prodrug comprises an opioid covalently bound to a promoiety comprising a GI enzyme-cleavable moiety, wherein cleavage of the GI enzyme-cleavable moiety by the enzyme mediates release of the opioid; and
detecting opioid prodrug conversion, wherein a decrease in opioid conversion in the presence of the GI enzyme inhibitor as compared to opioid conversion in the absence of the GI enzyme inhibitor indicates the opioid prodrug and GI enzyme inhibitor are suitable for formulation in a dose unit.

### Claim 56 (depends on 55)

The method of claim 55, wherein said administering comprises administering to the animal increasing doses of inhibitor co-dosed with a selected fixed dose of opioid prodrug.

### Claim 57 (depends on 55)

The method of claim 55, wherein said detecting facilitates identification of a dose of inhibitor and a dose of opioid prodrug that provides for a pre-selected pharmacokinetic (PK) profile.

### Claim 58 (depends on 55)

The method of claim 55, wherein said method comprises an in vivo assay.

### Claim 59 (depends on 55)

The method of claim 55, wherein said method comprises an ex vivo assay.

### Claim 60

A method for identifying an opioid prodrug and a GI enzyme inhibitor suitable for formulation in a dose unit, the method comprising:
administering to an animal tissue an opioid prodrug and a GI enzyme inhibitor, wherein the opioid prodrug comprises a opioid covalently bound to a promoiety comprising a GI enzyme-cleavable moiety, wherein cleavage of the GI enzyme-cleavable moiety by the enzyme mediates release of the opioid; and
detecting opioid prodrug conversion, wherein a decrease in opioid prodrug conversion in the presence of the GI enzyme inhibitor as compared to opioid prodrug conversion in the absence of the GI enzyme inhibitor indicates the opioid prodrug and GI enzyme inhibitor are suitable for formulation in a dose unit.

### Claim 61 (depends on 33)

The compound of claim 33, wherein R3 is hydrogen.

### Claim 62 (depends on 34)

The compound of claim 34, wherein R3 is hydrogen.

### Claim 63 (depends on 36)

The compound of claim 36, wherein R3 is hydrogen.

### Claim 64 (depends on 37)

The compound of claim 37, wherein R3 is hydrogen.

### Claim 65 (depends on 48)

The compound of claim 48, wherein R3 is hydrogen.

### Claim 66 (depends on 1)

The composition of claim 1, wherein the phenol-modified opioid prodrug is selected from the group consisting of the following formulae:
